Which of the following applications were recently granted accelerated approval by the FDA for adult and pediatric advanced or metastatic RET-altered thyroid cancer requiring systemic therapy?
In a study on the outcomes of hypofractionated stereotactic radiotherapy (HSRT) to the resection cavity vs whole-brain RT in patients with brain metastases, HSRT had a favorable risk-benefit profile.
The FDA has approved pralsetinib for the treatment of adult and pediatric patients with RET-mutated thyroid cancer.
In patients with SCLC, whole-brain RT yielded a superior time to central nervous system progression but no advantage in survival compared with stereotactic radiosurgery.
Molecular classification has strong prognostic value in high-risk endometrial cancer and should be incorporated in future trials to target subgroups of patients.
The evolution of RT techniques and therapies for melanoma brain metastases have improved outcomes among patients since 2007, according to a population-based study.
Study Recommends Preoperative CRT Followed By Nivolumab, Radical Surgery for MSS and MSI-High Advanced Rectal Cancer
Study findings suggest a regimen comprising nivolumab and radical surgery after chemoradiotherapy as a candidate therapy for locally advanced, MSS and MSI-H CRC.
With longer follow-up, patients with a controlled primary tumor and oligometastases receiving SABR had a greater rate of OS, according to findings from a phase 2 study.
Study findings suggest that EBRT plus brachytherapy boost (BT) may lessen OS versus EBRT plus ADT in certain patients with prostate cancer.